行情

MRTX

MRTX

Mirati
NASDAQ

实时行情|Nasdaq Last Sale

77.80
-4.46
-5.42%
交易中 10:38 03/31 EDT
开盘
81.40
昨收
82.25
最高
81.80
最低
77.53
成交量
8.58万
成交额
--
52周最高
132.59
52周最低
55.11
市值
33.83亿
市盈率(TTM)
-13.7666
分时
5日
1月
3月
1年
5年

分析师评级

15位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测MRTX价格均价为113.71,最高价位134.00,最低价为68.00。

EPS

MRTX 新闻

更多
  • Oppenheimer Maintains Outperform on Mirati Therapeutics, Lowers Price Target to $105
  • Benzinga · 1天前
  • Is Mirati Therapeutics, Inc. (MRTX) A Good Stock To Buy?
  • Insider Monkey · 4天前
  • Top Drug Stocks Under $5
  • MotleyFool.com · 5天前
  • Benzinga's Top Upgrades, Downgrades For March 12, 2020
  • Benzinga · 03/12 13:57

所属板块

生物技术和医学研究
+0.09%
制药与医学研究
+0.01%

热门股票

代码
价格
涨跌幅

MRTX 简况

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company develops product candidates to address the genetic and immunological promoters of cancer. Its clinical programs consist of two product candidates: MRTX849, a Kirsten Rat Sarcoma (KRAS) G12C inhibitor, and Sitravatinib, a multi-kinase inhibitor. Its KRAS inhibitor program is focused on the discovery and development of small molecule compounds that target KRAS G12C and G12D. MRTX849 is designed to inhibit KRAS G12C mutations which are present in non-small cell lung cancer (NSCLC) adenocarcinoma patients, colorectal cancer (CRC) patients, pancreatic cancer patients, as well as several other difficult-to-treat cancers. Sitravatinib is a spectrum-selective kinase inhibitor designed to inhibit receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.
展开

微牛提供Mirati Therapeutics Inc(NASDAQ-MRTX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的MRTX股票新闻,以帮助您做出投资决策。